Prognostic factors in patients after lobectomy for p-T1aN0M0 adenocarcinoma

European Journal of Cardio-thoracic Surgery

Volumn 41, Issue 3, 2012, Pages 603-606

  Igai, Hitoshi ^a   Matsuura, Natsumi ^a   Tarumi, Shintaro ^a   Chang, Sung Soo ^a   Misaki, Noriyuki ^a   Ishikawa, Shinya ^a   Yokomise, Hiroyasu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; pT1aN0M0

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SIZE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VASCULAR TUMOR; ADENOCARCINOMA; ADULT; CANCER STAGING; EPIDEMIOLOGY; LUNG RESECTION; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SEX DIFFERENCE; TREATMENT OUTCOME; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PNEUMONECTOMY; PROGNOSIS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84861426424     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezr006     Document Type: Article

References (19)

1. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602.
2. Lyons G, Quadrelli S, Silva C, Vera K, Iotti A, Venditti J et al. Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T-factor. J Thorac Oncol 2008; 3:989-93.
3. Gajra A, Newman N, Gamble GP, Abraham NZ, Kohman LJ, Graziano SL. Impact of tumor size on survival in stage I A non-small cell lung cancer: a case for subdividing stage I A disease. Lung Cancer 2003;42: 51-7.
4. Birim O, Kappetein AP, Takkenberg JJ, van Klaveren RJ, Bogers AJ. Survival after pathological stage I A non-small cell lung cancer: tumor size matters. Ann Thorac Surg 2005;79:1137-41.
5. Christian C, Erica S, Uliano M. The prognostic impact of tumor size in resected stage I non-small cell lung cancer: evidence for a two thresholds tumor diameters classification. Lung Cancer 2006;54:185-91.
6. Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg 2007;83:419-24.
7. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004;78:216-21.
8. Matsuguma H, Nakahara R, Igarashi S, Ishikawa Y, Suzuki H, Miyazawa N et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg 2008;135: 44-9.
9. Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S. Stage I A non-small cell lung cancer: vessel invasion is poor prognostic factor and a new adjuvant chemotherapy. Lung Cancer 2007;56:341-8.
10. Miyoshi K, Moriyama S, Kunimoto T, Nawa S. Prognostic impact of intra-tumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:429-34.
11. Tsuchiya T, Hashizume S, Akamine S, Muraoka M, Honda S, Tsuji K et al. Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer. Chest 2007;132:170-77.
12. Nakagawa T, Okumura N, Kokado Y, Miyoshi K, Matsuoka T, Kameyama K. Clinical relevance of intraoperative pleural lavage cytology in non-small cell lung cancer. Ann Thorac Surg 2007;83:204-8.
13. Ginsberg RL, Rubinstein LV, for the Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 1995;60:615-23.
14. Jowel WN. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010;15:3-5.
15. Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010;68: 319-31.
16. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B-I A non-small-cell lung cancer (Adjuvant Naverbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 2006;7: 719-27.
17. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
18. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarci-noma of the lung. N Engl J Med 2004;350:1713-21.
19. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephen RJ et al. A pooled analysis by LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.